Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Loqtorzi“
Suchtreffer
Begriffe & Kennungen
Loqtorzi · 4.8 · Immune-related colitis Immune-related colitis occurred in 0.7% (3/403) of patients receiving toripalimab in JU
Eintrag öffnenLoqtorzi · 4.8 · Immune-related endocrinopathies Immune-related adrenal insufficiency occurred in 0.2% (1/403) of patients rece
Eintrag öffnenLoqtorzi · 4.8 · Immune-related myocarditis Immune-related myocarditis occurred in 0.7% (3/403) of patients receiving toripalim
Eintrag öffnenLoqtorzi · 4.8 · Immune-related myositis Immune-related myositis occurred in 0.5% (2/403) of patients receiving toripalimab in
Eintrag öffnenLoqtorzi · 4.8 · Immune-related nephritis Immune-related nephritis occurred in 0.2% (1/403) of patients receiving toripalimab i
Eintrag öffnenLoqtorzi · 4.8 · Immune-related pneumonitis Immune-related pneumonitis occurred in 3.2% (13/403) patients receiving toripalimab
Eintrag öffnenLoqtorzi · 4.8 · Immune-related skin adverse reactions Immune-related skin adverse reactions occurred in 9.4% (38/403) of patie
Eintrag öffnenLoqtorzi · 4.8 · Immunogenicity As with all therapeutic proteins, there is potential for immunogenicity. In patients who receiv
Eintrag öffnenLoqtorzi · 4.8 · In patients receiving toripalimab in JUPITER-02 and JUPITER-06, hyperthyroidism occurred in 2.0% (8/403) of pa
Eintrag öffnenLoqtorzi · 4.8 · In patients receiving toripalimab in JUPITER-02 and JUPITER-06, hypophysitis occurred in 0.2% (1/403) of patie
Eintrag öffnenLoqtorzi · 4.8 · Infections and infestations Very common upper respiratory tract infection Common pneumonia, urinary tract infe
Eintrag öffnenLoqtorzi · 4.8 · Infusion related reactions Of the 403 patients who received toripalimab in combination with platinum containin
Eintrag öffnenLoqtorzi · 4.8 · No overall differences in safety were observed between patients ≥ 65 years of age and younger patients receivi
Eintrag öffnenLoqtorzi · 4.8 · Other immune-related adverse reactions Immune-related cystitis occurred in 0.5% (2/403) of patients receiving
Eintrag öffnenLoqtorzi · 4.8 · Overall, infusion related reactions occurred in 28 (1.8%) of 1514 patients treated with toripalimab, including
Eintrag öffnenLoqtorzi · 4.8 · Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medi
Eintrag öffnenLoqtorzi · 4.8 · Summary of the safety profile
Eintrag öffnenLoqtorzi · 4.8 · Table 2 includes only treatment related adverse drug reactions. The adverse reaction frequencies from clinical
Eintrag öffnenLoqtorzi · 4.8 · Table 2: Adverse reactions in patients treated with toripalimab
Eintrag öffnenLoqtorzi · 4.8 · Tabulated list of adverse reactions Adverse reactions observed in clinical studies of toripalimab as monothera
Eintrag öffnen